Riverbridge Partners LLC Sells 25,976 Shares of Charles River Laboratories International, Inc. $CRL

Riverbridge Partners LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 20.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 99,328 shares of the medical research company’s stock after selling 25,976 shares during the quarter. Riverbridge Partners LLC’s holdings in Charles River Laboratories International were worth $19,814,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its position in shares of Charles River Laboratories International by 11.2% during the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock valued at $124,000 after buying an additional 80 shares during the last quarter. Advisory Services Network LLC grew its position in shares of Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after buying an additional 83 shares during the last quarter. Rothschild Investment LLC grew its position in shares of Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Charles River Laboratories International by 4.2% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock worth $332,000 after acquiring an additional 85 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. raised its stake in shares of Charles River Laboratories International by 17.5% during the 3rd quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company’s stock worth $86,000 after acquiring an additional 87 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Down 0.4%

Charles River Laboratories International stock opened at $165.23 on Friday. The business’s 50-day simple moving average is $180.82 and its two-hundred day simple moving average is $180.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The company has a market cap of $8.13 billion, a PE ratio of -55.82, a PEG ratio of 2.84 and a beta of 1.64. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. During the same period last year, the business posted $2.66 earnings per share. The company’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Barclays decreased their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, February 19th. Mizuho lowered their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Citigroup boosted their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, UBS Group upped their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $206.15.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.